Efficiency of immunosuppressive therapy in virus-negative and virus-positive patients with morphologically verified lymphocytic myocarditis


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of immunosuppressive therapy (IST) in virus-negative (V–) and virus-positive (V+) patients with lymphocytic myocarditis (LM). Subjects and methods. 60 patients (45 males) (mean age 46.7±11.8 years) with dilated cardiomyopathy (mean left ventricular (LV) end diastolic size (EDS) 6.7±0.7 cm; ejection fraction (EF) 26.2±9.1%) were examined. The diagnosis of active/borderline LM was verified by right ventricular endomyocardial biopsy in 38 patients, by intraoperative LV biopsy in 10, in the study of explanted hearts from 3 patients and at autopsy in 9. The investigators determined the genomes of parvovirus B19, herpes viruses types 1, 2 and 6, Epstein—Barr (EBV), zoster, and cytomegalovirus in the blood and myocardium and, if antibodies were present in the blood, hepatitis B and C viruses, as well as antibodies against antigens in the endothelium, cardiomyocytes and their nuclei, smooth muscles, fibers of the conducting system. IST was used in terms of histological, immune, and viral activities. IST was performed in 22 V+ patients (Group 1) and in 24 V– patients (Group 2); this was not done in 10 V+ patients (Group 3) and V– patients (Group 4). IST comprised methylprednisolone at a mean dose of 24 mg/day (n=40), hydroxychloroquine 200 mg/day (n=20), azathioprine at a mean dose of 150 mg/day (n=21); antiviral therapy included acyclovir, ganciclovir, intravenous immunoglobulin (n=24). The follow-up period was 19 (7.3—40.3) months. Results. The viral genome was detected in the myocardium of 32 patients who made up a V+ group. The degree of histological activity did not differ in relation to the presence of viral genome in the myocardium. The degree of immune activity (anticardiolipin antibody titers) in the V+ patients was as high as that in V– ones. At baseline, the V+ patients had a significantly higher LV EDS and a lower EF than the V– patients. Overall, IST only could lead to a significant increase in EF (from 26.5±0.9 to 36.0±10.8%; p<0.001) and reductions in NYHA functional class from III to II (p<0.001), LV EDS (from 6.7±0.7 to 6.4±0.8 cm; p<0.01), pulmonary artery systolic pressure (from 48.9±15.5 to 39.4±11.5 mm Hg (p<0.01); the IST group had significantly lower mortality rates than the non-IST group (23.9 and 64.3%; p<0.01). At the same time, a significant trend was seen in both V– and V+ patients. The mortality rate in the V+ patients, as a whole, was higher (46.9 and 17.9%; p<0.05). Conclusion. IST leads to a significant improvement of functional indices and it is associated with lower mortality rates in both myocardial V– and V+ patients with LM. A more than 10% EF increase in the first 2 months is associated with a good prognosis. The presence of viral genome in the myocardium (primarily herpesviruses rather than parvovirus-19) is accompanied by more severe initial dysfunction, a less pronounced effect of IST, and higher mortality rates. However, the positive effect of IST also persists in V+ patients. No positive changes (a decrease in EF was observed) were absent only in IST-naïve V+ patients.

About the authors

O V Blagova

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

A V Nedostup

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

E A Kogan

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

V A Sulimov

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

References

  1. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648,2648a-2648d. https://doi.org/10.1093/eurheartj/eht210.
  2. Палеев Н.Р., Палеев Ф.Н. Классификация некоронарогенных заболеваний миокарда. Кардиология. 2008;48(9):53-58.
  3. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857-863.
  4. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30(16):1995-2002. https://doi.org/10.1093/eurheartj/ehp249
  5. Благова О.В., Недоступ А.В., Коган Е.А., Дземешкевич С.Л., Фролова Ю.В., Седов В.П., Гагарина Н.В., Сулимов В.А., Абугов С.А., Заклязьминская Е.В., Донников А.Е., Кадочникова В.В., Куприянова А.Г., Зайденов В.А., Белецкая Л.В. ДКМП как клинический синдром: опыт нозологической диагностики с применением биопсии и подходы к лечению. Терапевтический архив. 2011;83(9):41-48.
  6. Chen DY, Chen YM, Tzang BS, Lan JL, Hsu TC. Th17-related cytokines in systemic lupus erythematosus patients with dilated cardiomyopathies: a possible linkage to parvovirus B19 infection. PLoS One. 2014;9(12):e113889. https://doi.org/10.1371/journal.pone.0113889
  7. Lu C, Qin F, Yan Y, Liu T, Li J, Chen H. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown). 2014. https://doi.org/10.2459/ JCM.0000000000000134
  8. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793-2798.
  9. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32(21):2616-2625. https://doi.org/10.1093/eurheartj/ehr165
  10. Zimmermann O, Rodewald C, Radermacher M, Vetter M, Wiehe JM, Bienek-Ziolkowski M, Hombach V, Torzewski J. Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy? J Card Fail. 2010;16(4):348-356. https://doi.org/10.1016/j.cardfail.2009.12.016
  11. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;15(2):193-201. https://doi.org/10.3851/IMP1516
  12. Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev. 2013;18(6):761-795. https://doi.org/10.1007/s10741-012-9362-7
  13. Robinson J, Hartling L, Vandermeer B, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2015;(5):CD004370. https://doi.org/10.1002/14651858.CD004370.pub3
  14. Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J. 2015;79(1):4-7. https://doi.org/10.1253/circj.CJ-14-1192
  15. Kühl U, Schultheiss HP. Viral myocarditis. Swiss Med Wkly. 2014;144:w14010. https://doi.org/10.4414/smw.2014.14010
  16. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965-1970.
  17. Осипова Ю.В., Благова О.В., Недоступ А.В., Коган Е.А., Сулимов В.А., Фролова Ю.В., Дземешкевич С.Л., Донников А.Е., Кадочникова В.В., Куприянова А.Г., Зайденов В.А. Значимость различных неинвазивных маркеров в диагностике латентного миокардита в сопоставлении с данными биопсии. Кардиология и сердечно-сосудистая хирургия. 2015;8(1):40-56. https://doi.org/10.17116/kardio20158140-56
  18. Koepsell SA, Anderson DR, Radio SJ. Parvovirus B19 is a bystander in adult myocarditis. Cardiovasc Pathol. 2012;21(6):476-481. https://doi.org/10.1016/j.carpath.2012.02.002
  19. Camargo PR, Okay TS, Yamamoto L, Del Negro GM, Lopes AA. Myocarditis in children and detection of viruses in myocardial tissue: implications for immunosuppressive therapy. IntJ Cardiol. 2011;148(2):204-208. https://doi.org/10.1016/j.ijcard.2009.11.002
  20. Baumgratz JF, Vila JH, Silva JP, Fonseca Ld, Rodrigues EA, Knobel E. Cardiogenic shock due to cytomegalovirus myocarditis: successful clinical treatment. Rev Bras Cir Cardiovasc. 2010; 25(2):149-153.
  21. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49(3):151-157. https://doi.org/10.1016/j.jcv.2010.07.008
  22. Morales JM1, Kamar N, Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012;176:10-23. https://doi.org/10.1159/000333772
  23. Naniwa T, Maeda T, Shimizu S, Ito R. Hepatitis B virus-related polyarteritis nodosa presenting with multiple lung nodules and cavitary lesions. Chest. 2010;138(1):195-197. https://doi.org/10.1378/chest.09-2579
  24. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17):2073-2082. https://doi.org/10.1093/eurheartj/ehn296
  25. Andréoletti L, Lévêque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009; 102(6-7):559-568. https://doi.org/10.1016/j.acvd.2009.04.010

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies